Karyopharm Therapeutics I... (KPTI)
| Bid | 5.61 |
| Market Cap | 54.76M |
| Revenue (ttm) | 145.24M |
| Net Income (ttm) | -76.42M |
| EPS (ttm) | -13.95 |
| PE Ratio (ttm) | -0.46 |
| Forward PE | -0.64 |
| Analyst | Buy |
| Ask | 6.45 |
| Volume | 51,230 |
| Avg. Volume (20D) | 129,217 |
| Open | 6.08 |
| Previous Close | 6.07 |
| Day's Range | 5.94 - 6.41 |
| 52-Week Range | 3.51 - 18.00 |
| Beta | 0.59 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezo...
Analyst Forecast
According to 4 analyst ratings, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 745.07% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call TranscriptKaryopharm Therapeutics Inc. (NASDAQ:KPTI ) Q4 2024 Earnings Call February 19, 2025 8:00 AM ET Company Participants Brendan Strong - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - CMO &...
